ZNF346

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, ZNF346 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF346 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF346 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF346 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ZNF346 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PDACOSMedianII,III,IV0.4000.634.00181view →
GBMOSQuartileAll0.6470.366.0154view →
LSCCDFSTertileII,III,IV1.0000.851.0413view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF346–PDAC (OS)

Kaplan–Meier survival curve for ZNF346 mass-spec protein-high vs -low samples in PDAC.

Open the PDAC breakdown →

Exploration